SuperworthFractyl Health price to book ratio GUTS
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 5.2×
- Aug 2026
- 2-year median
- 2.5×
- 2-year range
- 1.0× to 16.4×
- Peer median
- 1.3×
Fractyl Health's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.
It was last meaningful in Aug 2026, at 5.2×.
On the days it had one over the last 2 years, its median was 2.5×, from 1.0× in Aug 2024 to 16.4× in Jun 2025.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.2× | 5.0× | 12.7× |
| 2025 | 7.4× | 1.4× | 16.4× |
| 2024 | 1.9× | 1.0× | 4.2× |
Against its peers
Companies in Medical - Instruments & Supplies nearest Fractyl Health's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| GUTSFractyl Health | n/m |
| NEPHNephros | 3.2× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 1.3× |
| Peer median | 1.3× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Fractyl Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.